Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Monday, May 13th. Analysts expect Praxis Precision Medicines to post earnings of ($2.01) per share for the quarter.
Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($2.97) EPS for the quarter, topping analysts' consensus estimates of ($3.05) by $0.08. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.30 million. Praxis Precision Medicines had a negative return on equity of 151.02% and a negative net margin of 5,037.88%. On average, analysts expect Praxis Precision Medicines to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.
Praxis Precision Medicines Stock Performance
PRAX traded down $1.31 during midday trading on Friday, reaching $48.78. 128,505 shares of the company were exchanged, compared to its average volume of 204,542. The company has a market cap of $834.53 million, a price-to-earnings ratio of -2.06 and a beta of 2.87. The company's fifty day moving average price is $53.69 and its 200 day moving average price is $36.86. Praxis Precision Medicines has a one year low of $12.45 and a one year high of $67.21.
Analysts Set New Price Targets
A number of analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $105.00 price target on shares of Praxis Precision Medicines in a research report on Friday, April 26th. Robert W. Baird assumed coverage on Praxis Precision Medicines in a research report on Wednesday, May 1st. They set an "outperform" rating and a $117.00 price target for the company. Jefferies Financial Group increased their price target on Praxis Precision Medicines from $75.00 to $128.00 and gave the company a "buy" rating in a research report on Tuesday, March 26th. Finally, Wedbush increased their price target on Praxis Precision Medicines from $16.00 to $29.00 and gave the company a "neutral" rating in a research report on Friday, January 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $105.80.
Read Our Latest Analysis on Praxis Precision Medicines
About Praxis Precision Medicines
(
Get Free Report)
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Recommended Stories
Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
